AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04545164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: CAD4TB
Description: CAD4TB is a Computer Aided Diagnosis (CAD) image processing algorithm that can aid interpretation of Chest X-ray images to accurately detect tuberculosis.
Study NCT04545164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FujiLAM
Description: Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
Study NCT04545164 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: FujiLAM
Description: Fujifilm SILVAMP TB LAM is a high sensitivity test for mycobacterial lipoarabinomannan (LAM) in urine samples.
Study NCT05797532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: breastfeeding
Description: The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance.
Study NCT05797532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: skin to skin contact
Description: The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance.
Study NCT05797532 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: swaddling and holding
Description: The NIPS (Neonatal Infant Pain Scale) pain score, heart rate and oxygen saturation of the newborn were recorded by the researcher in the study group, 2 minutes before the heel lance, 10 seconds during the heel lance, and 2 minutes after the heel lance was completed.~In order to determine the crying time of newborns in all three study groups, the voice recorder and stopwatch were turned on two minutes before and 2 minutes after the heel lance.
Study NCT02504112 — intervention group
Intervention type: OTHER
Intervention: there is no intervention
Study NCT01789138 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Situated Optimal Adherence Intervention
Description: Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
Study NCT02105493 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 500 microgram of Nitroglycerin
Description: 500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
Study NCT02105493 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline 5 mL
Description: Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
Study NCT03407495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IOP Injection (MPB-1523)
Description: one dose, once IV injection at Day 1
Study NCT02230761 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XOPH5 Ointment
Study NCT02230761 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03586323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: superior laryngeal nerve block with lidocaine
Description: SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
Study NCT03586323 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: superior laryngeal nerve block with lidocaine
Description: SLNB was performed with 4 ml of 1.5% lidocaine below the thyroid membrane
Study NCT03078790 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iPad
Description: a 10 minute electronic guided deep breathing module offered via an iPad
Study NCT02001415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spectacles
Description: Normal spectacle lenses were used to correct myopia as the control group.
Study NCT02001415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myovision
Description: Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
Study NCT06179797 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: remote ischemic conditioning
Description: suprasystolic BP sequential compression of both arms with blood pressure cuffs for 5 min on/off for 4 cycles.
Study NCT00941473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinilone (kenalog)
Description: Epidural steroid injection of 80mg of Triamcinilone.
Study NCT02701439 — intervention group
Intervention type: DEVICE
Intervention: Small membrane filtration
Description: Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:~* Abbreviated demographic and clinical evaluation~* TB history and evaluation~* Obtain three sputum samples - one early morning sample and two spot samples~* HIV testing (and CD4 if positive)~* Chest radiograph~* Small membrane filtration intervention will be administered to both arms
Study NCT03176329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing 1 : INTELLIVENT-ASV
Study NCT03176329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing 2 : INTELLIVENT-ASV
Study NCT03176329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing 1 : Conventional mode
Study NCT03176329 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nursing 2 : Conventional mode
Study NCT01879150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cyclaplex bone anchor
Description: Device implantation
Study NCT02467010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
Study NCT02467010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
Study NCT02467010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.~Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause.
Study NCT00447161 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bacillus Clausii Multi ATB Resist
Description: Twice daily dose of 1 vial of 1x10\^9 of Bacillus clausii spores, orally suspension in water
Study NCT00447161 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo
Study NCT00844688 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: sorafenib
Description: Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~1. Progression of disease.~2. The patient is unlikely to benefit from further treatment as~   Judged by the Investigator.~3. Intolerable toxicity of the drugs.~4. Withdrawal of consent for any reason.
Study NCT00844688 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Gemcitabine
Description: Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 \& 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:~Progression of disease. The patient is unlikely to benefit from further treatment as~Judged by the Investigator.~Intolerable toxicity of the drugs. Withdrawal of consent for any reason.
Study NCT00848081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tadalafil
Description: 5 mg taken by mouth once daily for 12 weeks
Study NCT00848081 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: By mouth once daily for 12 weeks
Study NCT03757689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pre-Surgery: Pembrolizumab, one 200mg dose; Post-Surgery: Pembrolizumab, 200 mg every 3 weeks.
Study NCT03757689 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Wide Excision and Sentinel Lymph Node (SLN) Biopsy
Description: Wide excision and SLN biopsy and pathologic assessment of tissue will be performed per standard of care.
Study NCT04026867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Linkage Navigation
Description: The Linkage Navigation arm will consist of an additional service layered onto clinician referral and will incorporate protocols from Antiretroviral Treatment and Access Studies (ARTAS), the most influential studies of HIV linkage-to-care to date.
Study NCT04026867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinician Referral
Description: The Clinician Referral arm will serve as an active control and baseline standard of care.
Study NCT04026867 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Referral
Description: The Clinician Referral arm will serve as an active control and baseline standard of care.
Study NCT03906903 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.
Study NCT03906903 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Repetitive Transcranial Magnetic Stimulation
Description: Subjects will receive both active and placebo rTMS, in a crossover modality.
Study NCT03906903 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Stimulation
Description: Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
Study NCT03906903 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Stimulation
Description: Subjects will receive 30 sessions of 30 minutes with Cognitive Stimulation in three areas (attention, memory and executive functions), one each week.
Study NCT04411875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine 10 mg
Description: The subjects randomly received single oral administration of amlodipine 10 mg.
Study NCT04411875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levamlodipine 5 mg
Description: The subjects randomly received single oral administration of levamlodipine 5 mg.
Study NCT04170114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Respiratory Physiotherapy
Description: All patients will receive comprehensive respiratory physiotherapy training by the physiotherapist. All patients will undergo comprehensive respiratory physiotherapy techniques twice daily for 8 weeks.~Comprehensive respiratory physiotherapy programme will include diaphragmatic breathing exercise, thoracic expansion exercises, incentive spirometer exercise (Triflo), oscillatory PEP (Flutter), postural drainage, coughing techniques and teaching respiratory control.
Study NCT04771507 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Ibrutinib will be stopped at inclusion in the and the patient will be followed OFF therapy. At clinical progress, ibrutinib will be restarted (ON period) at the same standard dose as used at inclusion. When the patient achieve at least partial response again, a new OFF period is started, and so on.
Study NCT00511667 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK0941
Description: MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Study NCT00511667 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
Study NCT02056704 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Angiography with IVUS
Description: The use of IVUS to evaluate dialysis access failure.
Study NCT03032731 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website and pedometer intervention
Description: Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
Study NCT02001415 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Orthokeratology
Description: Orthokeratology lenses.
Study NCT03069170 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Stem Cell Transplantation
Description: Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
Study NCT03032731 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Standard, publicly available NHS resources for healthy lifestyles.
Study NCT01679977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibrational-proprioceptive Resistance Exercise Training
Study NCT01679977 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuromuscular Electrical Stimulation Training
Study NCT03729856 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: intervention
Description: The adapted physical activity (APA) intervention is a theory-based physical activity (PA) promotion intervention. The APA model is comprised of 4 steps: 1) pre-participation evaluation of physiological, personal and environmental factors that influence PA adoption and maintenance; 2) application of individualised, evidence based strategies associated with increased PA participation tailored to the participant's motivational readiness; 3) development of structured exercise and/or lifestyle PA program; and 4) tailored relapse prevention strategies to maintain physical activity beyond the duration of the program. The intervention will be conducted in the participant's home environment.
Study NCT03729856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: B
Description: Participants will undertake their usual activities during the baseline period. An extended pre-intervention time frame is needed to establish a stable control phase and enhance internal validity.
Study NCT03729856 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Follow-up
Description: Participants will have no contact with intervention personnel during the 5 week follow-up, withdrawal period. The withdrawal phase enables initial assessment of physical activity behavior change.
Study NCT04161560 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab-IRDye800
Description: does of Cetuximab-IRDye800
Study NCT03847454 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: REACH
Description: The intervention consists of a mobility device called ActivLife developed by Alreh Medical, that is coupled with serious games, a Kinect sensor and a wearable sensor called Stepwatch, to continuously measure the patients physical activity.
Study NCT01618383 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: colonoscopy or rectosigmoidoscopy
Description: Usual procedure
Study NCT03234855 — intervention group
Intervention type: DEVICE
Intervention: LMD
Description: Physician uses LMD to measure defect during procedure.
Study NCT05660902 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ROM Exercises
Description: The patients were evaluated by the physician, they were put into practice when their condition was stable within the first 72 hours. In addition to their routine treatments, according to the ROM exercise protocol, which was created by taking expert opinions and reviewing the literature ROM exercises were performed by the researcher and health personnel trained by the researcher 3 times a day for 2 weeks, approximately 30 minutes. The movements were started with the upper extremity on the unaffected side and then moved to the affected upper extremity. After the exercise applied to the affected upper extremity was finished, the same exercise was applied to the intact lower extremity and the affected lower extremity. Only the resistance points were mobilized and the exercise applied in each joint was repeated at least three times without applying extra force.
Study NCT02664051 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalcrom
Description: Drug: disodium cromoglycate 100mg 4x2 daily~Other Names:~• Nalcrom
Study NCT02664051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 100mg 4x2 daily mannitol
Study NCT02200328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
Study NCT02200328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
Study NCT02673476 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-008176
Description: ALS-008176 tablets
Study NCT02673476 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Identical placebo tablets
Study NCT00985907 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxil, melphalan, bortezomib
Description: Doxil®: IV over 30-60 min, Day 1 q28d~Melphalan: IV over 30 min, Day 1 q28d~Velcade®: IV bolus, Day 1, 4, 8, 11 q28d~Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2~Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2~Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2
Study NCT04125056 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydronidone Capsule(Specification: 30 mg / grain）
Description: Test group
Study NCT04125056 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydronidone Capsule(Specification: 15 mg / grain）
Description: Control group
Study NCT01367223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: solution of amino acids supplemented with glutamine
Description: parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
Study NCT01367223 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: amino acids not supplemented with glutamine
Description: parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
Study NCT01480713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress® (Raltegravir, 400 mg every 12 hours)
Description: Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
Study NCT01480713 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isentress® (Raltegravir, 400 every 12 hours)
Description: Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours